TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic E3 ubiquitin ligase that was initially described as an autoantigen in autoimmune diseases and la...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/6/5140 |
| _version_ | 1797611410516082688 |
|---|---|
| author | Amelie von Bernuth Julika Ribbat-Idel Luise Klapper Tobias Jagomast Dirk Rades Anke Leichtle Ralph Pries Karl-Ludwig Bruchhage Sven Perner Anne Offermann Verena Sailer Christian Idel |
| author_facet | Amelie von Bernuth Julika Ribbat-Idel Luise Klapper Tobias Jagomast Dirk Rades Anke Leichtle Ralph Pries Karl-Ludwig Bruchhage Sven Perner Anne Offermann Verena Sailer Christian Idel |
| author_sort | Amelie von Bernuth |
| collection | DOAJ |
| description | Patients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic E3 ubiquitin ligase that was initially described as an autoantigen in autoimmune diseases and later associated with the intracellular antiviral response. Here, we investigated the role of TRIM21 as a biomarker candidate for HNSCC in predicting tumor progression and patient survival. We analyzed TRIM21 expression and its association with clinical-pathological parameters in our HNSCC cohort using immunohistochemistry. Our HNSCC cohort included samples from 419 patients consisting of primary tumors (<i>n</i> = 337), lymph node metastases (<i>n</i> = 156), recurrent tumors (<i>n</i> = 54) and distant metastases (<i>n</i> = 16). We found that cytoplasmic TRIM21 expression was associated with the infiltration of immune cells into primary tumors. In addition, TRIM21 expression was significantly higher in primary tumors than in lymph node metastases, and increased TRIM21 expression was correlated with shorter progression-free survival in HNSCC patients. These results suggest that TRIM21 could be a new biomarker for progression-free survival. |
| first_indexed | 2024-03-11T06:27:30Z |
| format | Article |
| id | doaj.art-d53dda13074743db9b9dc6e14bf6e46b |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T06:27:30Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-d53dda13074743db9b9dc6e14bf6e46b2023-11-17T11:29:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-03-01246514010.3390/ijms24065140TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCCAmelie von Bernuth0Julika Ribbat-Idel1Luise Klapper2Tobias Jagomast3Dirk Rades4Anke Leichtle5Ralph Pries6Karl-Ludwig Bruchhage7Sven Perner8Anne Offermann9Verena Sailer10Christian Idel11Institute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyDepartment of Radiation Oncology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyDepartment of Otorhinolaryngology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyDepartment of Otorhinolaryngology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyDepartment of Otorhinolaryngology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyInstitute of Pathology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyDepartment of Otorhinolaryngology, University of Luebeck, University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538 Luebeck, GermanyPatients with head and neck squamous cell carcinoma (HNSCC) continue to have a rather poor prognosis. Treatment-related comorbidities have negative impacts on their quality of life. TRIM21 is a cytosolic E3 ubiquitin ligase that was initially described as an autoantigen in autoimmune diseases and later associated with the intracellular antiviral response. Here, we investigated the role of TRIM21 as a biomarker candidate for HNSCC in predicting tumor progression and patient survival. We analyzed TRIM21 expression and its association with clinical-pathological parameters in our HNSCC cohort using immunohistochemistry. Our HNSCC cohort included samples from 419 patients consisting of primary tumors (<i>n</i> = 337), lymph node metastases (<i>n</i> = 156), recurrent tumors (<i>n</i> = 54) and distant metastases (<i>n</i> = 16). We found that cytoplasmic TRIM21 expression was associated with the infiltration of immune cells into primary tumors. In addition, TRIM21 expression was significantly higher in primary tumors than in lymph node metastases, and increased TRIM21 expression was correlated with shorter progression-free survival in HNSCC patients. These results suggest that TRIM21 could be a new biomarker for progression-free survival.https://www.mdpi.com/1422-0067/24/6/5140TRIM21head and neck squamous cell carcinoma (HNSCC)prognostic biomarkerimmune cell infiltrationIHC |
| spellingShingle | Amelie von Bernuth Julika Ribbat-Idel Luise Klapper Tobias Jagomast Dirk Rades Anke Leichtle Ralph Pries Karl-Ludwig Bruchhage Sven Perner Anne Offermann Verena Sailer Christian Idel TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC International Journal of Molecular Sciences TRIM21 head and neck squamous cell carcinoma (HNSCC) prognostic biomarker immune cell infiltration IHC |
| title | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC |
| title_full | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC |
| title_fullStr | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC |
| title_full_unstemmed | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC |
| title_short | TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC |
| title_sort | trim21 expression as a prognostic biomarker for progression free survival in hnscc |
| topic | TRIM21 head and neck squamous cell carcinoma (HNSCC) prognostic biomarker immune cell infiltration IHC |
| url | https://www.mdpi.com/1422-0067/24/6/5140 |
| work_keys_str_mv | AT amelievonbernuth trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT julikaribbatidel trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT luiseklapper trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT tobiasjagomast trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT dirkrades trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT ankeleichtle trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT ralphpries trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT karlludwigbruchhage trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT svenperner trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT anneoffermann trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT verenasailer trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc AT christianidel trim21expressionasaprognosticbiomarkerforprogressionfreesurvivalinhnscc |